MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur’s agreement to develop and commercialise MEDI8897.

Gowling WLG has advised on the transaction MEDI8897 is a monoclonal antibody for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Paolo Bossi

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here